Pawlik TM, Gleisner AL, Vigano L, Kooby DA, Bauer TW, Frilling A, et al. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. J Gastrointest Surg. 2007 Nov. 11 (11):1478-86; discussion 1486-7. [QxMD MEDLINE Link].
Aloia TA, Járufe N, Javle M, Maithel SK, Roa JC, Adsay V, et al. Gallbladder cancer: expert consensus statement. HPB (Oxford). 2015 Aug. 17 (8):681-90. [QxMD MEDLINE Link].
Jensen EH, Abraham A, Jarosek S, Habermann EB, Al-Refaie WB, Vickers SA, et al. Lymph node evaluation is associated with improved survival after surgery for early stage gallbladder cancer. Surgery. 2009 Oct. 146 (4):706-11; discussion 711-3. [QxMD MEDLINE Link].
[Guideline] NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. V 2.2022. National Comprehensive Cancer Network. Available at http://bit.ly/leKxOv. Version 3.2022 — October 14, 2022; Accessed: November 29, 2022.
Kobayashi S, Tomokuni A, Gotoh K, Takahashi H, Akita H, Marubashi S, et al. A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer. Eur J Surg Oncol. 2017 Apr. 43 (4):763-771. [QxMD MEDLINE Link].
McMasters KM, Tuttle TM, Leach SD, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg. 1997 Dec. 174(6):605-8; discussion 608-9. [QxMD MEDLINE Link].
Jung JH, Lee HJ, Lee HS, Jo JH, Cho IR, Chung MJ, et al. Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma. World J Gastroenterol. 2017 May 14. 23 (18):3301-3308. [QxMD MEDLINE Link].
Cho Y, Kim TH, Seong J. Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma. Strahlenther Onkol. 2017 Aug. 193 (8):620-629. [QxMD MEDLINE Link].
Sumiyoshi T, Shima Y, Okabayashi T, Negoro Y, Shimada Y, Iwata J, et al. Chemoradiotherapy for Initially Unresectable Locally Advanced Cholangiocarcinoma. World J Surg. 2018 Sep. 42 (9):2910-2918. [QxMD MEDLINE Link].
Engineer R, Goel M, Chopra S, Patil P, Purandare N, Rangarajan V, et al. Neoadjuvant Chemoradiation Followed by Surgery for Locally Advanced Gallbladder Cancers: A New Paradigm. Ann Surg Oncol. 2016 Sep. 23 (9):3009-15. [QxMD MEDLINE Link].
Kuriyama N, Usui M, Gyoten K, Hayasaki A, Fujii T, Iizawa Y, et al. Neoadjuvant chemotherapy followed by curative-intent surgery for perihilar cholangiocarcinoma based on its anatomical resectability classification and lymph node status. BMC Cancer. 2020 May 11. 20 (1):405. [QxMD MEDLINE Link]. [Full Text].
Le Roy B, Gelli M, Pittau G, Allard MA, Pereira B, Serji B, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg. 2018 Jun. 105 (7):839-847. [QxMD MEDLINE Link].
Matsuyama R, Mori R, Ota Y, Homma Y, Yabusita Y, Hiratani S, et al. Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma. Ann Surg Oncol. 2022 Apr. 29 (4):2393-2405. [QxMD MEDLINE Link].
Yadav S, Xie H, Bin-Riaz I, Sharma P, Durani U, Goyal G, et al. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. Eur J Surg Oncol. 2019 Aug. 45 (8):1432-1438. [QxMD MEDLINE Link].
Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012 Jul. 143 (1):88-98.e3; quiz e14. [QxMD MEDLINE Link].
Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl Int. 2010 Jul. 23 (7):692-7. [QxMD MEDLINE Link]. [Full Text].
Abdelrahim M, Al-Rawi H, Esmail A, Xu J, Umoru G, Ibnshamsah F, et al. Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series. Curr Oncol. 2022 May 17. 29 (5):3585-3594. [QxMD MEDLINE Link]. [Full Text].
Lunsford KE, Javle M, Heyne K, et al, Methodist–MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC). Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018 May. 3 (5):337-348. [QxMD MEDLINE Link].
Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol. 2015 Jan. 41 (1):120-7. [QxMD MEDLINE Link]. [Full Text].
Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, et al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2020 Jan 1. 6 (1):51-59. [QxMD MEDLINE Link]. [Full Text].
Cai Z, He C, Zhao C, Lin X. Survival Comparisons of Hepatic Arterial Infusion Chemotherapy With mFOLFOX and Transarterial Chemoembolization in Patients With Unresectable Intrahepatic Cholangiocarcinoma. Front Oncol. 2021. 11:611118. [QxMD MEDLINE Link]. [Full Text].
Edeline J, Lamarca A, McNamara MG, Jacobs T, Hubner RA, Palmer D, et al. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. Cancer Treat Rev. 2021 Sep. 99:102258. [QxMD MEDLINE Link]. [Full Text].
Konstantinidis IT, Groot Koerkamp B, Do RK, Gönen M, Fong Y, Allen PJ, et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016 Mar 1. 122 (5):758-65. [QxMD MEDLINE Link]. [Full Text].
Cercek A, Boerner T, Tan BR, ET AL. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2020 Jan 1. 6 (1):60-67. [QxMD MEDLINE Link]. [Full Text].
Pietge H, Sánchez-Velázquez P, Akhoundova D, Siebenhüner A, Winder T, Bachmann H, et al. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study. Oncology. 2021. 99 (5):300-309. [QxMD MEDLINE Link]. [Full Text].
Wright GP, Perkins S, Jones H, Zureikat AH, Marsh JW, Holtzman MP, et al. Surgical Resection Does Not Improve Survival in Multifocal Intrahepatic Cholangiocarcinoma: A Comparison of Surgical Resection with Intra-Arterial Therapies. Ann Surg Oncol. 2018 Jan. 25 (1):83-90. [QxMD MEDLINE Link].
Jolissaint JS, Soares KC, Seier KP, Kundra R, Gönen M, Shin PJ, et al. Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection. Clin Cancer Res. 2021 Jul 15. 27 (14):4101-4108. [QxMD MEDLINE Link].
Franssen S, Soares KC, Jolissaint JS, et al. Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma. JAMA Surg. 2022 Jul 1. 157 (7):590-596. [QxMD MEDLINE Link].
Holster JJ, El Hassnaoui M, Franssen S, IJzermans JNM, de Jonge J, Mostert B, et al. Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Ann Surg Oncol. 2022 Sep. 29 (9):5528-5538. [QxMD MEDLINE Link].
[Guideline] Gómez-España MA, Montes AF, Garcia-Carbonero R, Mercadé TM, Maurel J, Martín AM, et al. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). Clin Transl Oncol. 2021 May. 23 (5):988-1000. [QxMD MEDLINE Link]. [Full Text].
Bridgewater J, Fletcher P, Palmer DH, et al, BILCAP study group. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. J Clin Oncol. 2022 Jun 20. 40 (18):2048-2057. [QxMD MEDLINE Link].
Primrose JN, Fox RP, Palmer DH, et al, BILCAP study group. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019 May. 20 (5):663-673. [QxMD MEDLINE Link].
Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol. 2015 Aug 20. 33 (24):2617-22. [QxMD MEDLINE Link].
Neoptolemos JP, Moore MJ, Cox TF, et al, European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11. 308 (2):147-56. [QxMD MEDLINE Link].
Borghero Y, Crane CH, Szklaruk J, et al. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol. 2008 Nov. 15(11):3147-56. [QxMD MEDLINE Link].
Lim K, Oh D, Chie E, et al. Which is better in patients with curatively resected extrahepatic biliary tract cancer? Adjuvant concurrent chemoradiation (CCRT) alone versus CCRT followed by maintenance chemotherapy. ASCO Meeting Abstracts. 2008. 26:15659.
Lin LL, Picus J, Drebin JA, et al. A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma. Am J Clin Oncol. 2005 Jun. 28(3):234-41. [QxMD MEDLINE Link].
Das P, Wolff RA, Abbruzzese JL, et al. Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol. 2006 Oct 24. 1:41. [QxMD MEDLINE Link]. [Full Text].
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8. 362(14):1273-81. [QxMD MEDLINE Link].
Oh DY, Lee KH, Lee DW, Yoon J, Kim TY, Bang JH, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol. 2022 Jun. 7 (6):522-532. [QxMD MEDLINE Link].
Morizane C, Okusaka T, Mizusawa J, et al, members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019 Dec 1. 30 (12):1950-1958. [QxMD MEDLINE Link]. [Full Text].
Sharma A, Kalyan Mohanti B, Pal Chaudhary S, Sreenivas V, Kumar Sahoo R, Kumar Shukla N, et al. Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial. Eur J Cancer. 2019 Dec. 123:162-170. [QxMD MEDLINE Link].
Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005 Apr 1. 23(10):2332-8. [QxMD MEDLINE Link].
Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer. 2008 Jan 29. 98(2):309-15. [QxMD MEDLINE Link].
Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Jun. 21 (6):796-807. [QxMD MEDLINE Link]. [Full Text].
Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 May. 21 (5):671-684. [QxMD MEDLINE Link].
Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 Oct. 6 (10):803-815. [QxMD MEDLINE Link].
Goyal L, Meric-Bernstam F, Hollebecque A, Morizane C, Valle JW, Karasic TB, et al. Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements. JCO. 2022. 40:16_suppl:4009. [Full Text].
Wen PY, Stein A, van den Bent M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022 Jan. 23 (1):53-64. [QxMD MEDLINE Link].
Hong DS, DuBois SG, Kummar S,. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020 Apr. 21 (4):531-540. [QxMD MEDLINE Link].
Doebele RC, Drilon A, Paz-Ares L, et al, trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb. 21 (2):271-282. [QxMD MEDLINE Link]. [Full Text].
Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021 Sep. 22 (9):1290-1300. [QxMD MEDLINE Link].
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020 Jan 1. 38 (1):1-10. [QxMD MEDLINE Link].
Subbiah V, Cassier PA, Siena S, Garralda E, Paz-Ares L, Garrido P, et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat Med. 2022 Aug. 28 (8):1640-1645. [QxMD MEDLINE Link]. [Full Text].
Lamarca, A., Palmer, D. H., Wasan, H. S., et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021. 22(5):690-701. [QxMD MEDLINE Link]. [Full Text].
Yoo C, Kim KP, Jeong JH, Kim I, Kang MJ, Cheon J, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol. 1560-1572. [QxMD MEDLINE Link]. [Full Text].
André T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004 Sep. 15(9):1339-43. [QxMD MEDLINE Link].
LIM JY, JEUNG, et al. Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. 2008.
Chen JS, Chao Y, Yang TS, et al. A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma. Cancer Chemother Pharmacol. 2009 Dec. 65(1):151-7. [QxMD MEDLINE Link].
Kim TW, Chang HM, Kang HJ, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol. 2003 Jul. 14(7):1115-20. [QxMD MEDLINE Link].
Ducreux M, Rougier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol. 1998 Jun. 9(6):653-6. [QxMD MEDLINE Link].
Shibata T, Ebata T, Fujita KI, Shimokata T, Maeda O, Mitsuma A, et al. Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction. Cancer Sci. 2015 Nov 23. [QxMD MEDLINE Link].
Lamarca A, Benafif S, Ross P, Bridgewater J, Valle JW. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. Eur J Cancer. Sep 2015. 51(13):1694-1703. [QxMD MEDLINE Link]. [Full Text].
Park JS, Oh SY, Kim SH, et al. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol. 2005 Feb. 35(2):68-73. [QxMD MEDLINE Link].
Valle JW. Advances in the treatment of metastatic or unresectable biliary tract cancer. Ann Oncol. 2010 Oct. 21 Suppl 7:vii345-vii348. [QxMD MEDLINE Link].
Saluja SS, Gulati M, Garg PK, Pal H, Pal S, Sahni P, et al. Endoscopic or percutaneous biliary drainage for gallbladder cancer: a randomized trial and quality of life assessment. Clin Gastroenterol Hepatol. 2008 Aug. 6 (8):944-950.e3. [QxMD MEDLINE Link].
Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007 Mar 26. 96(6):896-902. [QxMD MEDLINE Link]. [Full Text].